Medera Expands Scientific Advisory Board with Leading Heart Failure and Cardiopulmonary Physiology Experts to Advance HFpEF Gene Therapy Program

Appointments further strengthen clinical leadership as Medera advances its First-In-Human HFpEF gene therapy program toward key upcoming milestones BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera”), a clinical-stage biopharmaceutical company developing next-generation disease-modifying cardiovascular therapeutics, today announced the appointment of three internationally recognized leaders in heart failure and cardiopulmonary physiology to its Scientific Advisory Board (SAB): Grego